Premium
Oral magnesium supplementation reduces insulin resistance in non‐diabetic subjects – a double‐blind, placebo‐controlled, randomized trial
Author(s) -
Mooren F. C.,
Krüger K.,
Völker K.,
Golf S. W.,
Wadepuhl M.,
Kraus A.
Publication year - 2011
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2010.01332.x
Subject(s) - insulin resistance , medicine , endocrinology , placebo , insulin , lipid profile , diabetes mellitus , type 2 diabetes , overweight , metabolic syndrome , blood pressure , obesity , alternative medicine , pathology
The incidence of insulin resistance and metabolic syndrome correlates with the availability of magnesium (Mg). We studied the effect of oral Mg supplementation on insulin sensitivity and other characteristics of the metabolic syndrome in normomagnesemic, overweight, insulin resistant, non‐diabetic subjects. Subjects were tested for eligibility using oral glucose tolerance test (OGTT) and subsequently randomized to receive either Mg–aspartate–hydrochloride (n = 27) or placebo (n = 25) for 6 months. As trial endpoints, several indices of insulin sensitivity, plasma glucose, serum insulin, blood pressure and lipid profile were determined. Mg supplementation resulted in a significant improvement of fasting plasma glucose and some insulin sensitivity indices (ISIs) compared to placebo. Blood pressure and lipid profile did not show significant changes. The results provide significant evidence that oral Mg supplementation improves insulin sensitivity even in normomagnesemic, overweight, non‐diabetic subjects emphasizing the need for an early optimization of Mg status to prevent insulin resistance and subsequently type 2 diabetes.